Sumanta Kumar Pal


Ontology type: schema:Person     


Person Info

NAME

Sumanta Kumar

SURNAME

Pal

Publications in SciGraph latest 50 shown

  • 2022-03-28 Shining a light on the psychological burden of cancer in NATURE MEDICINE
  • 2022-02-28 Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial in NATURE MEDICINE
  • 2022-01-03 Predictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages in NEOADJUVANT IMMUNOTHERAPY TREATMENT OF LOCALIZED GENITOURINARY CANCERS
  • 2021-09-15 Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma in BMC CANCER
  • 2021-08-07 Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma in BMC CANCER
  • 2021-05-03 Biomarker approach harnessed in trials of personalized medicine for bladder cancer in NATURE MEDICINE
  • 2021-03-27 A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations in INVESTIGATIONAL NEW DRUGS
  • 2021-03-23 Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2021-03-15 COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2020-10-22 COVID-19 and financial toxicity in patients with renal cell carcinoma in WORLD JOURNAL OF UROLOGY
  • 2020-10-02 Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2020-09-07 Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial in NATURE MEDICINE
  • 2020-06-19 Genomic profiling in renal cell carcinoma in NATURE REVIEWS NEPHROLOGY
  • 2020-03-17 Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers in NATURE REVIEWS UROLOGY
  • 2019-12-20 The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2019-12-18 Renal Cell Carcinoma in ONCOLOGY IN THE PRECISION MEDICINE ERA
  • 2019-10-08 First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options in TARGETED ONCOLOGY
  • 2019-09-14 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2019-06-07 Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database in BMC CANCER
  • 2019-04-01 The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2019-03-12 Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2018-10-05 Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma in NATURE MEDICINE
  • 2018-09-10 Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2018-09-01 Advances in the Treatment of Metastatic Renal Cell Carcinoma in GENITOURINARY CANCERS
  • 2018-07-27 Cytoreductive nephrectomy: questions remain after CARMENA in NATURE REVIEWS UROLOGY
  • 2018-06-04 Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma in NATURE MEDICINE
  • 2018-05-16 Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) in BRITISH JOURNAL OF CANCER
  • 2018-04-20 Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2018-02-20 The Role of Circulating Tumor DNA in Renal Cell Carcinoma in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2018-01-29 Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2018-01-25 Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2017-10-26 Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis in ADVANCES IN THERAPY
  • 2017-09-13 Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy in JOURNAL OF ROBOTIC SURGERY
  • 2016-11-16 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-06-29 Mucinous, Signet Ring, Ductal, and Sarcomatoid Variants of Prostate Cancer in RARE GENITOURINARY TUMORS
  • 2016-06-28 Finding a niche for girentuximab in metastatic renal cell carcinoma in NATURE REVIEWS UROLOGY
  • 2016 Renal Cancer Trends in Molecularly Targeted Therapies in ENCYCLOPEDIA OF CANCER
  • 2015-04-21 Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-02-24 Activin Receptor Inhibitors—Dalantercept in CURRENT ONCOLOGY REPORTS
  • 2015-01-20 Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2015-01 Sequencing Systemic Therapies for Metastatic Kidney Cancer in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2015-01 Piwi-Interacting RNAs (piRNAs) Are Dysregulated in Renal Cell Carcinoma and Associated with Tumor Metastasis and Cancer-Specific Survival in MOLECULAR MEDICINE
  • 2015 Emerging Agents in Renal Cell Carcinoma in KIDNEY CANCER
  • 2014-11-06 Targeted TLR9-activation/STAT3-blocking abrogates immunosuppressive functions of myeloid-derived suppressor cells from late-stage prostate cancer patients in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-11-01 Development and Incorporation of Biomarkers in RCC Therapeutics in RENAL CELL CARCINOMA
  • 2014-08-22 Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma in INVESTIGATIONAL NEW DRUGS
  • 2014-07-29 The best fit for enzalutamide in metastatic prostate cancer in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2014-04-01 First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC in BRITISH JOURNAL OF CANCER
  • 2014 Renal Cancer Trends in Molecularly Targeted Therapies in ENCYCLOPEDIA OF CANCER
  • 2012-11-13 Abiraterone and its place in the treatment of metastatic CRPC in NATURE REVIEWS CLINICAL ONCOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.410425.6", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.22072.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.280502.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412301.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4868.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.48336.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.223827.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412519.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.19006.3e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.26009.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.32224.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.42505.36", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.22937.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.492639.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14925.3b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.65499.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.15485.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.265219.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.22254.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.30760.32", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.154185.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.185648.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.50956.3f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.479969.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.267370.7", 
            "type": "Organization"
          }
        ], 
        "familyName": "Pal", 
        "givenName": "Sumanta Kumar", 
        "id": "sg:person.01162002222.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-08-04T17:38", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/person/person_869.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01162002222.57'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01162002222.57'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01162002222.57'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01162002222.57'


     

    This table displays all metadata directly associated to this object as RDF triples.

    64 TRIPLES      10 PREDICATES      35 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01162002222.57 schema:affiliation Naf14ff5a07f3467e8d217863261d839a
    2 grid-institutes:grid.14925.3b
    3 grid-institutes:grid.154185.c
    4 grid-institutes:grid.15485.3d
    5 grid-institutes:grid.185648.6
    6 grid-institutes:grid.19006.3e
    7 grid-institutes:grid.22072.35
    8 grid-institutes:grid.22254.33
    9 grid-institutes:grid.223827.e
    10 grid-institutes:grid.22937.3d
    11 grid-institutes:grid.26009.3d
    12 grid-institutes:grid.265219.b
    13 grid-institutes:grid.267370.7
    14 grid-institutes:grid.280502.d
    15 grid-institutes:grid.30760.32
    16 grid-institutes:grid.32224.35
    17 grid-institutes:grid.412301.5
    18 grid-institutes:grid.412519.a
    19 grid-institutes:grid.42505.36
    20 grid-institutes:grid.479969.c
    21 grid-institutes:grid.48336.3a
    22 grid-institutes:grid.4868.2
    23 grid-institutes:grid.492639.3
    24 grid-institutes:grid.50956.3f
    25 grid-institutes:grid.65499.37
    26 schema:familyName Pal
    27 schema:givenName Sumanta Kumar
    28 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57
    29 schema:sdDatePublished 2022-08-04T17:38
    30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    31 schema:sdPublisher N71c36e2567c64a949513fc6c4af34b7f
    32 sgo:license sg:explorer/license/
    33 sgo:sdDataset persons
    34 rdf:type schema:Person
    35 N71c36e2567c64a949513fc6c4af34b7f schema:name Springer Nature - SN SciGraph project
    36 rdf:type schema:Organization
    37 Naf14ff5a07f3467e8d217863261d839a schema:affiliation grid-institutes:grid.410425.6
    38 sgo:isCurrent true
    39 rdf:type schema:OrganizationRole
    40 grid-institutes:grid.14925.3b schema:Organization
    41 grid-institutes:grid.154185.c schema:Organization
    42 grid-institutes:grid.15485.3d schema:Organization
    43 grid-institutes:grid.185648.6 schema:Organization
    44 grid-institutes:grid.19006.3e schema:Organization
    45 grid-institutes:grid.22072.35 schema:Organization
    46 grid-institutes:grid.22254.33 schema:Organization
    47 grid-institutes:grid.223827.e schema:Organization
    48 grid-institutes:grid.22937.3d schema:Organization
    49 grid-institutes:grid.26009.3d schema:Organization
    50 grid-institutes:grid.265219.b schema:Organization
    51 grid-institutes:grid.267370.7 schema:Organization
    52 grid-institutes:grid.280502.d schema:Organization
    53 grid-institutes:grid.30760.32 schema:Organization
    54 grid-institutes:grid.32224.35 schema:Organization
    55 grid-institutes:grid.410425.6 schema:Organization
    56 grid-institutes:grid.412301.5 schema:Organization
    57 grid-institutes:grid.412519.a schema:Organization
    58 grid-institutes:grid.42505.36 schema:Organization
    59 grid-institutes:grid.479969.c schema:Organization
    60 grid-institutes:grid.48336.3a schema:Organization
    61 grid-institutes:grid.4868.2 schema:Organization
    62 grid-institutes:grid.492639.3 schema:Organization
    63 grid-institutes:grid.50956.3f schema:Organization
    64 grid-institutes:grid.65499.37 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...